Twist Bioscience Stock Rises Following Strategic Partnership with Eli Lilly

Key Facts

In a move reflecting the growing importance of innovation within the biotechnology sector, Twist Bioscience shares rose following the announcement of a partnership agreement with pharmaceutical giant Eli Lilly. According to reports, this strategic collaboration leverages Twist's technology platform, providing significant validation for the firm's business model and future revenue streams.

These developments occur as market data shows varying performance across sector-related entities; Eli Lilly (LLY) shares stood at $1139.925 at the close of September 16, 2026. Meanwhile, Twist Bioscience (TWST) had closed at $134.75 on September 14, 2026, highlighting investor reaction to high-profile alliances between biotech research firms and major pharmaceutical manufacturers.

Looking ahead, traders are monitoring liquidity levels for TWST after it reached a day high of $136.86 in its last recorded trading session. With no direct biotechnology sector catalysts in the upcoming economic calendar, market focus will remain on the operational details of this partnership and its long-term impact on the company's cash flows.